{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:45Z","timestamp":1787807865853,"version":"build-2784847793"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the cost-effectiveness of tremelimumab plus durvalumab [the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen] versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma in China using 5-year follow-up data from the HIMALAYA trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A three-state partitioned survival model comprising progression-free survival, progressed disease, and death was developed from the perspective of the Chinese healthcare system. Individual patient data were reconstructed from the published Kaplan\u2013Meier curves from the HIMALAYA trial and used to estimate and extrapolate progression-free and overall survival. The model used 28-day\u202fcycles, a 10-year base-case time horizon, and an annual discount rate of 4.5%. Only direct medical costs were included and expressed in 2025 United States dollars. The willingness-to-pay threshold was 27,906 USD per quality-adjusted life-year (QALY). One-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base-case analysis, the STRIDE regimen and sorafenib yielded 1.6937 and 1.2900 QALYs at total costs of 93,507.00 and 8,081.94 USD, respectively. The STRIDE regimen provided an additional 0.4037 QALYs at an incremental cost of 85,425.06 USD, resulting in an incremental cost-effectiveness ratio (ICER) of 211,596.11 USD\/QALY. The cost of durvalumab was the principal driver of the ICER. At the prespecified willingness-to-pay threshold, the probability that STRIDE was cost-effective was 0.0%. The ICER remained above the threshold in the durvalumab patient assistance program, 15-year time-horizon, alternative overall survival extrapolation, mixture-cure, and lower progressed-disease utility scenarios. The price of durvalumab would need to decrease by 92.34% for the ICER to reach the prespecified threshold. In contrast, reducing the price of tremelimumab to zero was insufficient to lower the ICER to the threshold when the price of durvalumab remained unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the STRIDE regimen improved health outcomes compared with sorafenib, it was not cost-effective at current prices in China. The findings suggest that its clinical value has not yet been matched by its economic value, primarily because of the high cumulative cost of durvalumab maintenance therapy. Future pricing, reimbursement, and patient assistance strategies should focus on reducing the cost of maintenance treatment to improve the value for money of the STRIDE regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1918118","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:14Z","timestamp":1787804774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Rui","family":"Feng","sequence":"first","affiliation":[{"name":"School of Disaster and Emergency Medicine, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liman","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lv","sequence":"additional","affiliation":[{"name":"School of Disaster and Emergency Medicine, Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref7","volume-title":"China Guidelines for Pharmacoeconomic Evaluations: 2025 Chinese\u2013English Bilingual Edition","author":"Wu","year":"2025"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"17588359241274625","DOI":"10.1177\/17588359241274625","article-title":"Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma","volume":"16","author":"Liao","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13561-024-00526-2","article-title":"Cost-effectiveness of immune checkpoint inhibitors as first-line therapy for advanced hepatocellular carcinoma: a systematic review","volume":"14","author":"Gong","year":"2024","journal-title":"Health Econ Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force\u20136","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.12449\/JCH240508","article-title":"Standard for diagnosis and treatment of primary liver cancer (2024 edition)","volume":"40","year":"2024","journal-title":"J Clin Hepatol"},{"key":"ref13","volume-title":"Guidelines of the Chinese Society of Clinical Oncology (CSCO): Hepatocellular Carcinoma 2024","year":"2024"},{"key":"ref14","first-page":"521","article-title":"Report on the nutrition and chronic diseases status of Chinese residents 2020","volume":"42","year":"2020","journal-title":"Acta Nutr Sin"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"ref16","year":""},{"key":"ref17","volume-title":"IMJUDO (Tremelimumab-Actl) Injection, for Intravenous use: Prescribing Information","year":"2022"},{"key":"ref18","year":""},{"key":"ref19","doi-asserted-by":"publisher","first-page":"869960","DOI":"10.3389\/fpubh.2022.869960","article-title":"Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0279786","DOI":"10.1371\/journal.pone.0279786","article-title":"First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.jhepr.2024.101130","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1356244","DOI":"10.3389\/fpubh.2024.1356244","article-title":"Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis","volume":"12","author":"Zheng","year":"2024","journal-title":"Front Public Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40273-024-01453-0","article-title":"Cost effectiveness of tremelimumab plus durvalumab for unresectable hepatocellular carcinoma in the USA","volume":"43","author":"Xiong","year":"2025","journal-title":"PharmacoEconomics"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e000094","DOI":"10.1136\/bmjmed-2021-000094","article-title":"Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness","volume":"1","author":"Latimer","year":"2022","journal-title":"BMJ Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"17562848241310314","DOI":"10.1177\/17562848241310314","article-title":"Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"18","author":"Zou","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"ref27","volume-title":"YERVOY (Ipilimumab) Injection: U.S. Prescribing Information","year":"2025"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1918118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:18Z","timestamp":1787804778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1918118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":27,"alternative-id":["10.3389\/fpubh.2026.1918118"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1918118","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1918118"}}